Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758924 · ClinicalTrials.gov registry record · Phase 2
Study of ANAVEX2-73 in Patients With Rett Syndrome
A Phase 2 study, sponsored by Anavex Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03758924 is a Phase 2 study that has completed, run by Anavex Life Sciences. The registered enrollment target is 31 participants.
The verdict
NCT03758924, a Phase 2 study, has completed, sponsored by Anavex Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Interventions
- DRUG Placebo
- DRUG ANAVEX2-73
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03758924
The ClinicalTrials.gov registry entry for NCT03758924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anavex Life Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03758924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03758924 about?
NCT03758924 is a clinical study titled "Study of ANAVEX2-73 in Patients With Rett Syndrome". Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the...
What is the current status of trial NCT03758924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-02-28. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03758924?
The interventions under investigation include: Placebo (DRUG), ANAVEX2-73 (DRUG).
Who is sponsoring clinical trial NCT03758924?
This trial is sponsored by Anavex Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.